[1]
|
J. H. Noseworthy, “Progress in Determing the Causes and Treatment of Multiple Sclerosis,” Nature, Vol. 399, 1999, pp. A40-A47.
|
[2]
|
L. Steinman, “Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System,” Cell, Vol. 85, No. 3, 1996, pp. 229-302
|
[3]
|
M. Tiberio, D. T. Chard, G. R. Altmann, et al., “Metabolite Changes in Early Relapsing-Remitting Multiple Sclerosis. A Two Year Follow-Up Study,” Journal of Neurology, Vol. 253, No. 2, 2006, pp. 224-230
|
[4]
|
C. Behl, “Oxidative Stress in Alzheimer’s Disease: Implications for Prevention and Therapy,” Sub-Cellular Biochemistry, Vol. 38, 2005, pp. 65-78.
doi:10.1007/0-387-23226-5_3
|
[5]
|
Z. Gu, T. Nakamura, D. Yao, Z. Q. Shi, et al., “Nitrosative and Oxidative Stress Links Dysfunctional Ubiquitination to Parkinson’s Disease,” Cell Death and Differentiation, Vol. 12, No. 9, 2005, pp. 1202-1204.
doi:10.1038/sj.cdd.4401705
|
[6]
|
H. Tremlett and J. Oger, “Hepatic Injury, Liver Monitoring and the Be-ta-Interferons for Multiple Sclerosis,” Journal of Neurology, Vol. 251, No. 11, 2004, pp. 1297- 1303. doi:10.1007/s00415-004-0619-5
|
[7]
|
L. Durelli, B. Ferrero, A. Oggero, et al., “Betaferon Safety Trial (BEST) Study Group. Liver and Thyroid Function and Autoimmunity during Interferon-Beta 1b Treatment for MS,” Neurology, Vol. 57, No. 8, 2001, pp. 1363-1370.
|
[8]
|
G. Niederwieser, W. Buchinger, R. M. Bonelli, et al., “Prevalence of Autoimmune Thyroiditis and Non-Immune Thyroid Disease in Multiple Sclerosis,” Journal of Neurology, Vol. 250, No. 6, 2003, pp. 672-675.
doi:10.1007/s00415-003-1053-9
|
[9]
|
F. Giubilei, G. Antonini, S. Di Legge, et al., “Blood Cholesterol and MRI Activity in First Clinical Episode Suggestive of Multiple Sclerosis,” Acta Neurologica Scandinavica, Vol. 106, No. 2, 2002, pp. 109-112.
doi:10.1034/j.1600-0404.2002.01334.x
|
[10]
|
S. Sotgiu, M. Pugliatti, A. Sanna, et al., “Serum Uric Acid and Multiple Sclerosis,” Neurological Sciences, Vol. 23, No. 4, 2002, pp. 183-188.
doi:10.1007/s100720200059
|
[11]
|
G. Toncev, B. Milicic, S. Toncev, et al., “Serum Uric Acid Levels in Multiple Sclerosis Patients Correlate with Activity of Disease and Blood-Brain Barrier Dysfunction,” European Journal of Neurology, Vol. 9, No. 3, 2002, pp. 221-226.
doi:10.1046/j.1468-1331.2002.00384.x
|
[12]
|
G. Toncev, B. Milicic, S. Toncev and G. Samardzic, “High-Dose Methylprednisolone Therapy in Multiple Sclerosis Increases Serum Uric Acid Levels,” Clinical Chemistry and Laboratory Medicine, Vol. 40, No. 5, 2002, pp. 505-508.
|
[13]
|
T. Vial and J. Descotes, “Clinical Toxicity of the Interferons,” Drug Safety, Vol. 10, No. 2, 1994, pp. 115-150.
doi:10.2165/00002018-199410020-00003
|
[14]
|
F. Mon-zani, N. Caraccio, A. Casolaro, F. Lombardo, G. Moscato, L. Murri, E. Ferrannini and G. Meucci, “Long-Term Interferon Beta-1b Therapy for MS: Is Routine Thyroid Assessment Always Useful,” Neurology, Vol. 55, No. 4, 2000, pp. 549-552.
|
[15]
|
P. Rieckmann, P. O’Connor, G. S. Francis, G. Wetherill and E. Alteri, “Haematological Effects of Interferon-Beta-1a (Rebif) Therapy in Multiple Sclerosis,” Drug Safety, Vol. 27, No. 10, 2004, pp. 745-756.
doi:10.2165/00002018-200427100-00005
|
[16]
|
P. V. Byskosh and A. T. Reder, “Interferon Beta-1b Effects on Cytokine mRNA in Peripheral Mononuclear Cells in Multiple Sclerosis,” Multiple Sclerosis, Vol. 1, No. 5, 1996, pp. 262-269.
|
[17]
|
C. S. Constantinescu, P. Freitag and L. Kappos, “Increase in Serum Levels of Uric Acid, an Endogenous Antioxidant, under Treatment with Glatiramer Acetate for Multiple Sclerosis,” Multiple Sclerosis, Vol. 6, No. 6, 2000, pp. 378-381.
|
[18]
|
V. B. Morra, G. Coppola, G. Orefice, et al., “Interferon- Beta Treatment Decreases Cholesterol Plasma Levels in Multiple Sclerosis Patients,” Neurology, Vol. 62, No. 5, 2004, pp. 829-830.
|
[19]
|
G. Coppola, R. Lanzillo, C. Florio, et al., “Long-Term Clinical Experience with Weekly Interferon Beta-1a in Relapsing Multiple Sclerosis,” European Journal of Neurology, Vol. 13, No. 9, 2006, pp. 1014-1021.
doi:10.1111/j.1468-1331.2006.01422.x
|
[20]
|
R. W. Baker, H. Sanders, R. H. Thompson, et al., “Serum Cholesterol Linoleate Levels in Multiple Sclerosis,” Journal of Neurology, Neurosurgery & Psychiatry, Vol. 28, No. 3, 1965, pp. 212-217
|
[21]
|
F. Lolli, B. Mazzanti, M. Pazzagli, et al., “The Glycopeptide CSF114 (Glc) Detects Serum Antibodies in Multiple Sclerosis,” Journal of Neuroimmunology, Vol. 167, No. 1-2, 2005, pp. 131-137.
doi:10.1016/j.jneuroim.2005.05.016
|
[22]
|
R. Lanzillo, G. Orefice, M. Quarantelli, et al., “Atorvastatin Combined to Interferon to Verify the Efficacy (ACTIVE) in Relapsing Remitting Active Multiple Sclerosis Patients: A Longitudinal Controlled Trial of Combination Therapy,” Multiple Sclerosis, Vol. 16, No. 4, 2010, pp. 450-454. doi:10.1177/1352458509358909
|
[23]
|
M. Togha, S. A. Karvigh, M. Nabavi, et al., “Simvastatin Treatment in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Interferon Beta 1a: A Double-Blind Randomized Controlled Trial,” Multiple Sclerosis, Vol. 16, No. 7, 2010, pp. 848-854.
doi:10.1177/1352458510369147
|